About Resverlogix
Resverlogix is a company based in Calgary (Canada) founded in 2001.. Resverlogix has raised $115.9 million across 19 funding rounds from investors including Shenzhen Hepalink Pharmaceutical and Yorkville Advisors. The company has 18 employees as of December 31, 2024. Resverlogix offers products and services including Apabetalone. Resverlogix operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Calgary, Canada
- Employees 18 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Resverlogix Corp.
-
Annual Revenue
$0 (USD)0as on Dec 31, 2024
-
Net Profit
$-7.27 M (USD)53.71as on Dec 31, 2024
-
EBITDA
$-4.09 M (USD)21.29as on Dec 31, 2024
-
Total Equity Funding
$115.9 M (USD)
in 19 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Oct 06, 2020
-
Investors
Shenzhen Hepalink Pharmaceutical
& 1 more
-
Employee Count
18
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Resverlogix
Resverlogix is a publicly listed company on the TSX with ticker symbol RVX in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Resverlogix
Resverlogix offers a comprehensive portfolio of products and services, including Apabetalone. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Epigenetic inhibitor for treating cardiovascular and chronic diseases.
Unlock access to complete
Funding Insights of Resverlogix
Resverlogix has successfully raised a total of $115.9M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 19
- Last Round Post-IPO — $10.0M
-
First Round
First Round
(01 Jan 2010)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Post-IPO - Resverlogix | Valuation |
investors |
|
| Aug, 2020 | Amount | Post-IPO - Resverlogix | Valuation |
investors |
|
| Sep, 2019 | Amount | Debt – Conventional - Resverlogix | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Resverlogix
Resverlogix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Shenzhen Hepalink Pharmaceutical and Yorkville Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Heparin Sodium API and derivatives are manufactured for global markets.
|
Founded Year | Domain | Location | |
|
Offers flexible capital to micro-cap and small-cap firms for growth.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Resverlogix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Resverlogix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Resverlogix Comparisons
Competitors of Resverlogix
Resverlogix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Resverlogix
Frequently Asked Questions about Resverlogix
When was Resverlogix founded?
Resverlogix was founded in 2001 and raised its 1st funding round 9 years after it was founded.
Where is Resverlogix located?
Resverlogix is headquartered in Calgary, Canada. It is registered at Calgary, Alberta, Canada.
Is Resverlogix a funded company?
Resverlogix is a funded company, having raised a total of $115.9M across 19 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $12M, raised on Jan 01, 2010.
How many employees does Resverlogix have?
As of Dec 31, 2024, the latest employee count at Resverlogix is 18.
What does Resverlogix do?
Resverlogix was founded in 2001 and is headquartered in Calgary, Canada. Operations are focused on the biopharmaceutical sector, where late-stage clinical development of small molecule BET-inhibitors targets cardiovascular disease in diabetes patients. The lead candidate, Apabetalone (RVX-208), is advanced as a selective bromodomain inhibitor for BRD4-BD2. A proprietary epigenetics platform supports drug discovery, with additional compounds identified for BET protein targeting.
Who are the top competitors of Resverlogix?
Resverlogix's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Resverlogix offer?
Resverlogix offers Apabetalone.
Is Resverlogix publicly traded?
Yes, Resverlogix is publicly traded on TSX under the ticker symbol RVX.
Who are Resverlogix's investors?
Resverlogix has 2 investors. Key investors include Shenzhen Hepalink Pharmaceutical, and Yorkville Advisors.
What is Resverlogix's ticker symbol?
The ticker symbol of Resverlogix is RVX on TSX.